Genprex, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GNPX | BDRX | SLXN | TOVX | PCSA | SIGHT.PA | |
|---|---|---|---|---|---|---|
| Market cap | 1.75M | 1.41M | 2.34M | 8.72M | 5.41M | 17.22M |
| P/E (TTM) | — | 0.0 | — | 0.3 | — | — |
| Forward P/E | -1.0 | — | -0.2 | -1.0 | -0.5 | -0.1 |
| Price/book | 0.1 | 0.0 | 19.2 | 0.7 | -17.0 | -0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −97.93% | −98.73% | −99.46% | −29.63% | −75.51% | −48.74% |
| Today | −7.36% | −4.61% | +0.59% | +4.40% | −0.26% | +1.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GNPX news ›Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)｜Beyond Biotech
"We're not going to be the magic company that does it. I think we're going to be working together collectively with industry to move treatments forward." Genprex CEO Ryan Confer explains how GPX002, a one-time AAV gene therapy using PDX1…
Promising Gene Therapy Supporting Applications Beyond Oncology; Key Presentation at Upcoming Gerontological Society of America Meeting: Genprex, Inc. (Nasdaq: GNPX)
Promising Gene Therapy Supporting Applications Beyond openPR.com Promising Gene Therapy Supporting Applications Beyond Oncology; Key Presentation at Upcoming Gerontological Society of America Meeting: Genprex, Inc. (Nasdaq: GNPX) Press…
Genprex Receives Notice of Allowance from the Canadian Intellectual Property Office for Patent Covering Reqorsa Gene Therapy Combination with PD-1 or PD-L1 Antibodies to Treat Cancer
Genprex, Inc. has announced that The Canadian Intellectual Property Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa Gene Therapy in combination with... has announced that The Canadian…
Genprex, Inc. Auditor Raises 'Going Concern' Doubt
Genprex, Inc. filed its 10-K on Mar 30, 2026 for the period ending Dec 31, 2025. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can... Biotechnology & Medical Research…
Genprex, Inc. Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging
Genprex, Inc. highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and ... highlighted new peer-reviewed…
Genprex, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Genprex, Inc. with the company of your choice via a Relative Strength chart. Real-time GNPX price, Nasdaq stock exchange Relative Strength Chart Genprex, Inc. Biotechnology & Medical Research All financial news and data tailored to…
Genprex Inc Announces Positive Clinical Data on Reqorsa Gene Therapy At Asco Annual Meeting
Genprex, Inc. announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology Annual Meeting taking place May 29 ? June... announced that its research…
Genprex, Inc. Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer
Genprex, Inc. announced that its research collaborators presented at the 2026 American Association for Cancer Research Annual Meeting being held April 17-22, 2026 in San Diego, California. The... announced that its research collaborators…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com4
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.